- Home
- DHIL vs ORGO Comparison
DHIL vs ORGO Comparison
Compare DHIL & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHIL | ORGO |
|---|---|---|
| Founded | 1990 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 348.6M |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | DHIL | ORGO |
|---|---|---|
| Price | $172.81 | $2.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 24.5K | ★ 665.8K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | 14.37 | ★ 1600.00 |
| EPS | ★ 17.91 | 0.15 |
| Revenue | $145,201,729.00 | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.84 |
| P/E Ratio | ★ $9.67 | $17.40 |
| Revenue Growth | 6.69 | ★ 17.04 |
| 52 Week Low | $114.11 | $2.57 |
| 52 Week High | $173.70 | $7.08 |
Technical Indicators
Market Signals| Indicator | DHIL | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 65.08 | 21.93 |
| Support Level | $170.59 | N/A |
| Resistance Level | N/A | $5.08 |
| Average True Range (ATR) | 0.81 | 0.22 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 74.52 | 1.87 |
Price Performance
Historical ComparisonAbout DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.